Effect of the compound GIZH -290 and levetiracetam on epileptic activity in rat brain structures on EEG models of bemegrid-induced seizures
https://doi.org/10.37489/2587-7836-2020-4-14-18
Abstract
The effect of levetiracetam (a derivative of 4-phenylpyrrolidone) and its original analog, the compound GIZH-290, on primary generalized epileptic activity (EpA) in rat brain structures (sensorimotor cortex, dorsal hippocampus-CA3 field and lateral hypothalamus field) on EEG models of bemegridinduced seizures was studied. It was found that EpA, after the introduction of bemegrid, appears in 1–2 minutes in the form of prolonged generalized high-amplitude discharges and is registered within 3 hours. GIZH-290 (5 mg/kg, intraperitoneal, 15 minutes after bemegrid) causes a significant (p < 0.05) decrease in the number of epileptic discharges in the cortex and at the level of the trend in the hippocampus, which is accompanied by a decrease in the amplitude of the Epi-discharges. Levetiracetam at a dose of 200 mg / kg does not significantly change the severity of paroxysmal activity (the number of convulsive discharges and their duration) caused by bemegrid.
About the Authors
T. A. Voronina
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Voronina Tatiana A. – D. Sci. in Medicine, professor, Head Laboratory of psychopharmacology
Moscow
S. A. Litvinova
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Litvinova Svetlana A. – PhD in Biology, leading researcher Laboratory of psychopharmacology
Moscow
I. G. Kovalev
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Kovalev Ivan G. – junior researcher Laboratory of psychopharma-cology
Moscow
References
1. Voronina TA, Avakyan GG, Nerobkova LN et al. New biomolecular targets for antiepileptic drugs. Epilepsy and Paroxysmal conditions. 2015;7(4):59–65. (In Russ). DOI:10.17749/2077-8333.2015.7.4.059-065
2. Karlov VA. Epilepsy in children and adult women and men: a guide for doctors. Second edition. Moscow: BINOM; 2019. (In Russ). ISBN 978-5-6042641-0-2
3. Lason W Chlebicka M, Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep. 2013;65(4):787-801. DOI:10.1016/s1734-1140(13)71060-0
4. Kovalev IG, Voronina TA, Litvinova SA et al. Comparison of the anticonvulsant and mnemotropic properties of new derivatives of 4-phenylpyrrolidone, Levetiracetam, and Piracetam in outbred mice and rats. Eksperimental'naia i Klinicheskaia Farmakologiia. 2017;80(6):13–18. (In Russ). DOI: 10.30906/0869-2092-2017-80-6-13-18
5. Voronina TA, Nerobkova LN. Guidance on Preclinical Evaluation of Medicines. Part 1. Moscow: Grif I K; 2012:235–250. (In Russ).
6. Tatti R, Haley MS, Swanson OK et al. Neurophysiology and Regulation of the Balance Between Excitation and Inhibition in Neocortical Circuits. Biol Psychiatry. 2017;81(10):821–831. DOI: 10.1016/j.biopsych.2016.09.017
7. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85-110. DOI: 10.1016/S0074-7742(06)81006-8
8. Kovalev IG, Bokov RO, Kudrin VS et al. The brain excitatory and inhibitory amino acids content in rats with lithium-pilocarpine-evoked seizures and after the preliminary administration of Levetiracetam and novel racetam derivative GIZH-290. Farmakokinetika i farmakodinamika. 2017;(4):19–24. (In Russ).
9. Kovalev IG, Vasilyeva EV, Kondrakhin EA et al. The Role of Glutamate and GABA Receptors in the Anticonvulsive Effects of Levetiracetam and a 4-Phenylpirrolidone Derivative (GIZh-290) in Rats. Neurochemistry. 2017;34(4):335–343. (In Russ). DOI:10.7868/S1027813317040057
10. Kumar K, Sharma S, Kumar P, Deshmukh R. Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders. Pharmacol Biochem and Behav. 2013;110:174-84. DOI: 10.1016/J.PBB.2013.07.003
11. Snead OC. Antiabsence seizure activity of specific GABAB and gammaHydroxybutyric acid receptor antagonists. Pharmacol Biochem and Behav. 1996;53(1):73-9. DOI: 10.1016/0091-3057(95)00200-6
12. Loscher W, Gillard M, Sands ZA et al. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016;30(11):1055- 1077. DOI: 10.1007/S40263-016-0384-X
13. Xu T, Bajjalieh SM. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001;3(8):691–698. DOI: 10.1038/35087000
14. Vogl C, Mochida S, Wolff C et al. The synaptic vesicle glycoprotein SV2A ligand Levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Mol Pharmacol. 2012;82(2):199-208. DOI: 10.1124/mol.111.076687
Review
For citations:
Voronina T.A., Litvinova S.A., Kovalev I.G. Effect of the compound GIZH -290 and levetiracetam on epileptic activity in rat brain structures on EEG models of bemegrid-induced seizures. Pharmacokinetics and Pharmacodynamics. 2020;(4):14-18. (In Russ.) https://doi.org/10.37489/2587-7836-2020-4-14-18
Views:
536
Email this article 